MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical ...
MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line ...
Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Application (BLA) Filing at This Time, Pending Further Analysis Top-line results from an interim analysis of ...
MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on ...
Following the release of Q1 2023 results, MiMedx Group, Inc. shares are soaring on double-digit revenue growth and bottom line on track to turn a profit. MiMedx Group, Inc. is a Marietta, ...
Under the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane allograft products to Zimmer to be marketed non-exclusively on a private label basis. Zimmer will market and sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results